Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Sandha, V. Ponnezhan, A. Lu, C. Lee, A. Balekian (Los Angeles, United States Of America). Predictors of esophageal dilatation in patients with idiopathic pulmonary fibrosis. Eur Respir J 2013; 42: Suppl. 57, 2364

Member's Comments

No comment yet.

Related content which might interest you: Changes in the small airways in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Volumetric CT analysis of normal lung as a predictor of mortality in idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Subtypes of pulmonary emphysema on HRCT affect prognosis on combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Interstitial lung abnormalities with a diagnosis of idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Translational and other aspects of idiopathic interstitial pneumonia Year: 2021 Diagnostic utility of surgical lung biopsies in elderly patients with interstitial lung diseases Source: International Congress 2015 – New insights into IIPs Year: 2015 Assessment of nutritional status in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Pirfenidone in patients with advanced idiopathic pulmonary fibrosis: First experience Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Comparison between patients with idiopathic pulmonary fibrosis and patients with pulmonary involvement of the usual interstitial pneumonia pattern that preceded the onset of rheumatoid arthritis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Non-pulmonary comorbidities in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Proportion of idiopathic pulmonary fibrosis among interstitial lung disease in a tertiary care center and its response to treatment Source: International Congress 2014 – ILDs 5 Year: 2014 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 The clinical value of surgical lung biopsy in 166 patients with suspected interstitial lung disease Source: International Congress 2015 – New insights into IIPs Year: 2015 Aquoaporin-1 expression in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Role of midkine in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Baseline characteristics and survival of patients with pulmonary hypertension in interstitial lung disease in the “HYPID” study Source: Annual Congress 2013 –Pulmonary circulation: clinical physiology Year: 2013 Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016